Genetic Testing, Genetics, Research, News, FEATURED
Obsolete Guidelines for Genetic Testing Miss Breast Cancer Patients Who Could Benefit
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? Approximately 330,000 patients are diagnosed with breast cance...
FEATURED, News, Genomics, Radiation, Risk Assessment, Regional Management
Influence of the subtype on local recurrence risk of breast cancer with or without radiotherapy
Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence Studies have shown that certain intrinsic subtypes of breast cancer are associate...
FEATURED, News, Genomics, Risk Assessment, Histology
Standard Light Microscopy Illuminates a Molecular Mystery
Why do triple negative breast cancers in BRCA-1 patients have a better prognosis?
FEATURED, News, Genetics, Genetic Testing, Risk Assessment
Genome-wide Association Studies (GWAS) may be future for helping determine relative risk
Genetics have a thumb on the scale for just about every human trait Francis Collins, current Director of the NIH and member of the Human Genome Project, predic...
Neoadjuvant Treatment, BRCA, PARP Inhibitors, FEATURED, News
Neoadjuvant Single-Agent PARP Inhibitor Appears Promising in BRCA Patients
BRCA patients may be able to take only one pill a day in a neoadjuvant setting The results of a small phase II trial suggest that the PARP inhibitor, talazopari...
Risk Factors Identified for Recurrence after NeoAdjuvant Therapy
Simple clinical score assists decision-making following neoadjuvant therapy There is an increased use of neoadjuvant therapy (NAC) despite a lack of survival be...
“Biosimilars” OK for Your Patients: Same Effectiveness. Lower Cost.
Trastuzumab Biosimilar ABP 980 Study Demonstrated Clinical Non-Inferiority Biosimilars are biologic products that are highly similar but have no clinically mean...
Breast surgeons now advocating genetic testing on all cancer patients
Current Eligibility Guidelines Omit Patients Who Could Benefit From Genetic Testing: Studies Show 30% of BRCA and 50% of all mutations missed when following cri...
